ClinicalTrials.gg
CompletedNCT01592864Updated Mar 10, 2014Results posted

The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity

A Phase 3 interventional study of Stannous Fluoride and Sodium Monofluorophosphate in Dentine Hypersensitivity, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-10.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Dentin Sensitivity by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dentin Sensitivity · GlaxoSmithKline.

Enrollment
20th of 28
120 · median 164
Started
2012
with 3 others
Phase 3
5 of 28
none open now
Registered
3rd of 28
by date

Among the 28 studies in Dentin Sensitivity by GlaxoSmithKline, this one is the 20th largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 3rd registered.

Dentin Sensitivity

290 studies on the registry are indexed under Dentin Sensitivity; 48 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

None of the 28 studies in Dentin Sensitivity by GlaxoSmithKline is open now. The open studies under Dentin Sensitivity, anywhere →

Who these studies take

Of the 19 Dentin Sensitivity studies recruiting now, 6 (32%) set no upper age limit and 12 (63%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Dentin Sensitivity by GlaxoSmithKline as a file.
02

Study summary

A study to compare the efficacy of a test dentifrice against a control dentifrice in reducing dentinal hypersensitivity over an eight week treatment period.

03

Conditions studied

  • Dentine Hypersensitivity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Subjects who suffer from tooth sensitivity

Inclusion Criteria:

  • none
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Arm 1

    Dentifrice containing stannous fluoride

    Drug: Stannous Fluoride

  • Active comparator
    Arm 2

    Marketed dentifrice containing Sodium Monofluorophosphate

    Drug: Sodium Monofluorophosphate

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 8

    Response to a constant jet of air applied to hypersensitive teeth is evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

    Time frame: Baseline to 8 weeks post administration of study treatment

Secondary outcomes

  1. Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 4

    Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

    Time frame: Baseline to 4 weeks post administration of study treatment

  2. Adjusted Mean Change From Baseline in Tactile Sensitivity Pain Response at Week 8

    Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. The constant pressure probe allowed the examiner to vary the force applied to the dentin surface from 10 grams (g) to an upper threshold of 80 g, in increments of 10g since the values below represents adjusted mean change in baseline, the value can fall below scale range. The greater the pressure the subject was able to tolerate, the less. Change from baseline in tactile response to Week 8 was calculated. sensitive the tooth. According to this tactile sensitivity assessment, an increasing force was applied to hypersensitive tooth until a yes response is recorded or the maximum force has been reached.

    Time frame: Baseline to 8 weeks post administration of study treatment

  3. Adjusted Mean Change From Baseline in Tactile Sensitivity Pain Response at Week 4

    Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. The constant pressure probe allowed the examiner to vary the force applied to the dentin surface from 10g to an upper threshold of 80g, in increments of 10g. The greater the pressure the subject was able to tolerate, the less sensitive the tooth. According to this tactile sensitivity assessment, an increasing force was applied to hypersensitive tooth until a yes response is recorded or the maximum force has been reached. Change from baseline in tactile response to Week 4 was calculated

    Time frame: Baseline to 4 weeks post administration of study treatment

07

Results

Posted Mar 10, 2014

Participant flow

Participants were recruited at the clinical site.

Participant flow — Overall Study
MilestoneStannous Fluoride (SnF) DentifriceSodium Monofluorophosphate (NaMFP) Dentifrice
Started6058
Completed6057
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryMean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 8

Response to a constant jet of air applied to hypersensitive teeth is evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

Time frame:
Baseline to 8 weeks post administration of study treatment
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 8
Score on a scaleSnF DentifriceNaMFP Dentifrice
Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 8-0.9 ± 0.68-0.5 ± 0.44
Statistical analysis
  • SnF Dentifrice vs NaMFP Dentifrice · ANCOVA · p = <0.0001 (No adjustment made for multiple comparisons, as primary comparison was pre-specified.) · Adjusted mean difference: -0.4 · 95% CI -0.6 to -0.2Difference is 0.454% SnF minus 0.76% NaMFP such that a negative difference favours first named treatment.
SecondaryMean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 4

Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

Time frame:
Baseline to 4 weeks post administration of study treatment
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 4
Score on a scaleSnF DentifriceNaMFP Dentifrice
Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 4-0.7 ± 0.58-0.2 ± 0.43
Statistical analysis
  • SnF Dentifrice vs NaMFP Dentifrice · ANCOVA · p = <0.0001 (No adjustment made for multiple comparisons, as primary comparison was pre-specified.) · Adjusted mean difference: -0.4 · 95% CI -0.6 to -0.3Difference is 0.454% SnF minus 0.76% NaMFP such that a negative difference favours first named treatment.
SecondaryAdjusted Mean Change From Baseline in Tactile Sensitivity Pain Response at Week 8

Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. The constant pressure probe allowed the examiner to vary the force applied to the dentin surface from 10 grams (g) to an upper threshold of 80 g, in increments of 10g since the values below represents adjusted mean change in baseline, the value can fall below scale range. The greater the pressure the subject was able to tolerate, the less. Change from baseline in tactile response to Week 8 was calculated. sensitive the tooth. According to this tactile sensitivity assessment, an increasing force was applied to hypersensitive tooth until a yes response is recorded or the maximum force has been reached.

Time frame:
Baseline to 8 weeks post administration of study treatment
Reported as:
Mean · grams
Adjusted Mean Change From Baseline in Tactile Sensitivity Pain Response at Week 8
gramsSnF DentifriceNaMFP Dentifrice
Adjusted Mean Change From Baseline in Tactile Sensitivity Pain Response at Week 821.3 ± 21.804.2 ± 6.18
Statistical analysis
  • SnF Dentifrice vs NaMFP Dentifrice · ANCOVA · p = <0.0001 (No adjustment made for multiple comparisons, as primary comparison was pre-specified.) · Adjusted mean difference: 16.9 · 95% CI 11.1 to 22.8Difference is 0.454% SnF minus 0.76% NaMFP such that a positive difference favours first named treatment.
SecondaryAdjusted Mean Change From Baseline in Tactile Sensitivity Pain Response at Week 4

Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. The constant pressure probe allowed the examiner to vary the force applied to the dentin surface from 10g to an upper threshold of 80g, in increments of 10g. The greater the pressure the subject was able to tolerate, the less sensitive the tooth. According to this tactile sensitivity assessment, an increasing force was applied to hypersensitive tooth until a yes response is recorded or the maximum force has been reached. Change from baseline in tactile response to Week 4 was calculated

Time frame:
Baseline to 4 weeks post administration of study treatment
Reported as:
Mean · grams
Adjusted Mean Change From Baseline in Tactile Sensitivity Pain Response at Week 4
gramsSnF DentifriceNaMFP Dentifrice
Adjusted Mean Change From Baseline in Tactile Sensitivity Pain Response at Week 411.2 ± 15.951.5 ± 3.86
Statistical analysis
  • SnF Dentifrice vs NaMFP Dentifrice · ANCOVA · p = <0.0001 (No adjustment made for multiple comparisons, as primary comparison was pre-specified.) · Adjusted mean difference: 9.6 · 95% CI 5.4 to 13.9Difference is 0.454% SnF minus 0.76% NaMFP such that a positive difference favors first named treatment.

Adverse events

Collected over All adverse events encountered or spontaneously reported following administration of any investigational product, or for up to 5 days after the last administration of investigational product were recorded.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SnF Dentifrice—0/60 (0%)1/60 (1.7%)
NaMFP Dentifrice—1/58 (1.7%)0/58 (0%)
Most frequent serious events
Most frequent serious events
EventSnF DentifriceNaMFP Dentifrice
CholecystitisHepatobiliary disorders0/601/58
Most frequent other events
Most frequent other events
EventSnF DentifriceNaMFP Dentifrice
Oral HerpesInfections and infestations1/600/58

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SnF DentifriceNaMFP DentifriceTotal
Mean36.9 ± 10.935.5 ± 10.636.2 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)SnF DentifriceNaMFP DentifriceTotal
Female463783
Male142135
08

Study locations

1 site
  • BioSci Research America, Inc.
    Las Vegas, Nevada 89121, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2012
First posted
May 7, 2012
Start
Mar 2012
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Mar 10, 2014
Last update
Mar 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01592864
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 7, 2012
Start date
Mar 2012
Primary completion
May 2012
Completion
May 2012
Results posted
Mar 10, 2014
Last update
Mar 10, 2014

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tin Fluorides

Start the discussion